Immune-related intestinal pseudo-obstruction associated with nivolumab treatment in a lung cancer patient

被引:12
|
作者
Fragulidis, Georgios [1 ]
Pantiora, Eirini [1 ]
Michalaki, Vasiliki [2 ]
Kontis, Elissaios [1 ]
Primetis, Elias [3 ]
Vezakis, Antonios [1 ]
Polydorou, Andreas [1 ]
机构
[1] Univ Athens, Aretaieio Hosp, Sch Med, Dept Surg 2, 76 Vas Sophias Ave, Athens 11528, Greece
[2] Univ Athens, Aretaieio Hosp, Sch Med, Dept Oncol, Athens, Greece
[3] Univ Athens, Aretaieio Hosp, Sch Med, Dept Radiol 1, Athens, Greece
关键词
Immune-related pseudo-obstruction; nivolumab; lung adenocarcinoma; immune checkpoint inhibitor; adverse effects; CHECKPOINT INHIBITORS; DOCETAXEL;
D O I
10.1177/1078155217738325
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Immune checkpoint inhibition therapy using targeted monoclonal antibodies is a new therapeutic approach with significant survival benefit for patients with several cancer types. However, their use can be associated with unique immune-related adverse effects as a consequence of impaired self-tolerance due to loss of T-cell inhibition via a nonselective activation of the immune system. Nivolumab is an anti-PD-1 immune checkpoint inhibitor that was recently developed for cancer immunotherapy with remarkable responses in nonsmall cell lung cancer patients. We present a 62-year-old Caucasian male with recurrent lung adenocarcinoma and currently under third-line therapy with nivolumab, who was admitted in our hospital with abdominal distension. Radiologic findings were consistent with small bowel ileus. After four days of conservative treatment, the patient underwent exploratory laparotomy where no cause of ileus was discovered. Postoperative the ileus persisted and considering that an adverse effect of the immune checkpoint inhibition therapy occurred, the patient received high-dose prednisone resulting in gradual improvement of symptoms. Immune checkpoint inhibitors may induce adverse effects to unaffected organ systems and tissues including the skin, gastrointestinal, hepatic, pulmonary, and endocrine system. The mainstay treatment consists of immunosuppression with corticosteroids in the majority of cases. As the clinical use of immune checkpoint inhibitors is expanding rapidly, there is an emergence of unique immune-related adverse effects in a growing patient population. Gaining early awareness is essential in these patients in order to ensure prompt diagnosis and management.
引用
收藏
页码:487 / 491
页数:5
相关论文
共 50 条
  • [1] Immune-related intestinal pseudo-obstruction caused by immune checkpoint inhibitors: case report
    Qian, Yimeng
    Zhi, Zheng
    Ai, Jing
    Kang, Lin
    Qiu, Gang
    Huang, Xin
    Zhao, Jing
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [2] Immune-related pancreatitis secondary to nivolumab in a patient with recurrent lung adenocarcinoma: A case report
    Ikeuchi, Kazuhiko
    Okuma, Yusuke
    Tabata, Taku
    LUNG CANCER, 2016, 99 : 148 - 150
  • [3] Immune-related Colitis Induced by the Long-term Use of Nivolumab in a Patient with Non-small Cell Lung Cancer
    Yasuda, Yuichiro
    Urata, Yoshiko
    Tohnai, Rie
    Ito, Shoichi
    Kawa, Yoshitaka
    Kono, Yuko
    Hattori, Yoshihiro
    Tsuda, Masahiro
    Sakuma, Toshiko
    Negoro, Shunichi
    Satouchi, Miyako
    INTERNAL MEDICINE, 2018, 57 (09) : 1269 - 1272
  • [4] Immune-related keratitis is a rare complication associated with nivolumab treatment in a patient with advanced colorectal cancer: A case report
    Su, Yuqi
    Li, Guoquan
    Xu, Jiaxin
    Zheng, Jiale
    Jiao, Jiapeng
    Zhang, Jianhui
    Gu, Xiaokang
    Cai, Zhai
    Luo, Hongyu
    Li, Zhou
    Han, Shuai
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [5] Immune-Related Adverse Events in Patients with Lung Cancer
    Correia, Guilherme Sacchi de Camargo
    Pai, Tanmayi
    Li, Shenduo
    Connor, Dana
    Zhao, Yujie
    Lou, Yanyan
    Manochakian, Rami
    CURRENT ONCOLOGY REPORTS, 2023, 25 (11) : 1259 - 1275
  • [6] FDG PET/CT in Immune-Related Arthritis in a Patient Treated With Nivolumab
    Bayat, Mohadeseh
    Doroudinia, Abtin
    Karam, Mehrdad Bakhshayesh
    Mehrian, Payam
    CLINICAL NUCLEAR MEDICINE, 2023, 48 (03) : 271 - 272
  • [7] Treatment of steroid-refractory immune checkpoint inhibitor induced intestinal pseudo obstruction with infliximab
    Dai, Cong
    Huang, Yu-Hong
    REVISTA ESPANOLA DE ENFERMEDADES DIGESTIVAS, 2024, 116 (07) : 383 - 384
  • [8] Early Onset Immune-Related Adverse Event to Identify Pseudo-Progression in a Patient With Ovarian Cancer Treated With Nivolumab: A Case Report and Review of the Literature
    Li, Hui
    Zhou, Xin
    Zhang, Ding
    Wang, Guoqiang
    Cheng, Xiaochun
    Xu, Caihong
    Yao, Bin
    Pang, Linrong
    Chen, Jun
    FRONTIERS IN MEDICINE, 2020, 7
  • [9] Serious Immune-related Adverse Events Are Associated With Greater Efficacy of Nivolumab Therapy Against Non-small Cell Lung Cancer
    Blazek, Jiri
    Hosek, Petr
    Hrabcova, Karolina
    Bratova, Monika
    Kultan, Juraj
    Hrnciarik, Michal
    Cernovska, Marketa
    Zemanova, Petra
    Krejci, Jana
    Koubkova, Leona
    Stastny, Marek
    Svaton, Martin
    IN VIVO, 2023, 37 (05): : 2229 - 2236
  • [10] Early Immune-Related Adverse Events and Association with Outcome in Advanced Non-Small Cell Lung Cancer Patients Treated with Nivolumab: A Prospective Cohort Study
    Teraoka, Shunsuke
    Fujimoto, Daichi
    Morimoto, Takeshi
    Kawachi, Hayato
    Ito, Munehiro
    Sato, Yuki
    Nagata, Kazuma
    Nakagawa, Atsushi
    Otsuka, Kojiro
    Uehara, Keiichiro
    Imai, Yukihiro
    Ishida, Kaori
    Fukuoka, Junya
    Tomii, Keisuke
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (12) : 1798 - 1805